Preclinical and clinical data with bispecific antibodies recruiting myeloid effector cells for tumor therapy.

@article{Ojik2001PreclinicalAC,
  title={Preclinical and clinical data with bispecific antibodies recruiting myeloid effector cells for tumor therapy.},
  author={Heidi H van Ojik and Thomas Valerius},
  journal={Critical reviews in oncology/hematology},
  year={2001},
  volume={38 1},
  pages={47-61}
}
Bispecific antibodies constitute a novel approach to improve antibody efficacy. In vitro, constructs to recruit myeloid effector cells have been extensively investigated, and first animal data in human Fc receptor transgenic mice confirmed their promising therapeutic potential. Clinical experience with these constructs demonstrated acceptable toxicity, and support therapeutic efficacy in subgroups of patients. However, limited availability, unacceptable immunogenicity, and unfavorable… CONTINUE READING